TNF Pharmaceuticals, Inc. (TNFA)

TNF Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	2023	2022	2021	2020	2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-17.69	-4	-15.2	-29.89	-9.49	-9.64
Depreciation & Amortization	-	-	-	-	0.02	0.02
Other Amortization	-	-	-	0.61	1.19	0.24
Loss (Gain) From Sale of Investments	-0	-0	0	0	-	-
Stock-Based Compensation	2.26	3.05	0.7	0.09	0.86	3.58
Other Operating Activities	2.9	-12.84	-	14.85	2.19	-
Change in Accounts Payable	2.46	1.04	1.69	-4.27	0.56	0.49
Change in Other Net Operating Assets	0.4	-0.23	0.54	-0.91	0.02	-0
Operating Cash Flow	-9.67	-12.98	-12.27	-19.52	-4.66	-5.32
Cash Acquisitions	-	-	-	1.38	-	-
Investment in Securities	-0.99	1.85	6.91	18.47	-	-
Investing Cash Flow	-0.99	1.85	6.91	19.85	-	-
Short-Term Debt Issued	-	-	-	1.83	1.27	0.01
Long-Term Debt Issued	-	-	-	0.12	1.43	1.92
Total Debt Issued	-	-	-	1.95	2.7	1.93
Long-Term Debt Repaid	-	-	-	-3.06	-	-
Net Debt Issued (Repaid)	-	-	-	-1.12	2.7	1.93
Issuance of Common Stock	-	-	5.55	1.19	1.98	2.96
Financing Cash Flow	11.11	13.07	5.55	0.07	4.68	4.89
Net Cash Flow	0.44	1.93	0.19	0.41	0.01	-0.43
Free Cash Flow	-9.67	-12.98	-12.27	-19.52	-4.66	-5.32
Free Cash Flow Per Share	-4.94	-8.42	-9.48	-16.72	-4.96	-4.19
Cash Interest Paid	-	-	0.01	0.27	-	-
Levered Free Cash Flow	-2.49	-5.27	-6.6	-4.28	-0.93	-1.71
Unlevered Free Cash Flow	-2.49	-5.27	-6.6	-4.51	-1.37	-1.79
Change in Net Working Capital	-3.62	-1.91	-2.26	1.92	-0.93	-0.49

Source: S&P Capital IQ. Standard template. Financial Sources.